文献速递血栓与止血

延长半衰期凝血因子浓缩物对美国重型血友病预防治疗的影响

The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States.
PubMed 文献 · Am J Hematol · 2020-01-01

基于ATHN数据集(145家血友病治疗中心),比较2018年6月至2019年3月重型血友病患者使用延长半衰期(EHL)与标准半衰期(SHL)产品进行预防治疗的情况,并从7家中心招募队列比较出血率、关节健康评分与生活质量。EHL使用持续增加,重型血友病A中28.4%使用EHL,重型血友病B中57.5%使用EHL;EHL使用有降低年化出血率的趋势,但未改善关节健康评分或生活质量。

要点

  • 截至2019年3月,重型血友病A中28.4%使用EHL,64.0%继续使用SHL,非因子产品增至7.1%。
  • 重型血友病B中57.5%使用EHL。
  • EHL使用在重型血友病A和B中有降低年化出血率的趋势,但未改善关节健康评分或生活质量。

核心结论

  • 美国重型血友病中EHL使用持续增加,但重型血友病A因非因子治疗可及而增速较慢;EHL在临床实践中的影响应继续前瞻性研究。

研究设计与样本

  • 使用ATHN数据集(145家ATHN附属血友病治疗中心)比较2018年6月至2019年3月重型血友病中EHL与SHL产品的使用。
  • 从7家参与中心招募患者队列,比较不同产品类别的年化出血率、血友病关节健康评分和生活质量。

主要发现

  • 截至2019年3月,重型血友病A中接受EHL者占28.4%,非因子产品处方增至7.1%,继续接受SHL者占64.0%。
  • 重型血友病B中多数接受EHL治疗,截至2019年3月占57.5%。
  • 重型血友病A和B中使用EHL有年化出血率降低的趋势,但未改善血友病关节健康评分或生活质量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With licensure of extended half-life (EHL) factor products and the changing landscape of available hemophilia products, patients and providers have options for less treatment-intense prophylaxis. The impact of these products in clinical practice to date remains understudied. We aimed to quantify the use of EHL products in prophylaxis in the US using the ATHN-dataset, a database of 145 ATHN-affiliated hemophilia treatment centers (HTCs). Further, we aimed to quantify the impact of EHL on key hemophilia indicators including annualized bleed rates (ABRs), hemophilia joint health scores (HJHS) and quality of life (QOL) metrics. The use of EHL vs standard half-life (SHL) products in severe hemophilia was compared between June 2018 and March 2019 using the ATHN-dataset. A cohort of patients was also recruited from seven participating HTCs in order to compare ABR, HJHS and QOL between product classes. By March 2019 the number of individuals with severe Hemophilia A (SHA) receiving EHLs remained relatively stable (28.4%), whereas the number of prescribed non-factor products increased to 7.1%, with a diminishing majority of patients (64.0%) continuing to receive SHLs. The majority of patients with severe hemophilia B (SHB) received treatment with EHLs including 57.5% by March 2019. There was a trend toward lower ABR with use of EHLs in SHA and SHB, although this did not result in improved HJHS nor QOL. EHL use in the United States in severe hemophilia continues to increase, although at a slower rate in SHA with the availability of non-factor therapy. The impact of the EHL therapies in clinical practice should continue to be examined prospectively.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Malec LM, Cheng D, Witmer CM, et al. The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. Am J Hematol. 2020. PMID: 32356313. doi:10.1002/ajh.25844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。